The role of medicinal cannabis in clinical therapy: Pharmacists' perspectives

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Isaac, Sami ^a   Saini, Bandana ^a   Chaar, Betty B ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; CANNABIDIOL; CANNABINOL; DRONABINOL; MEDICAL CANNABIS; NABILONE; NABIXIMOLS; CANNABINOID;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ANOREXIA; ANTIEMETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; AUSTRALIA; AWARENESS; CHRONIC DISEASE; CHRONIC PAIN; CONTROLLED STUDY; DRUG LEGISLATION; FEMALE; GILLES DE LA TOURETTE SYNDROME; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; LEGAL PROCEDURE; MALE; MEDICAL PRACTICE; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NEUROPATHIC PAIN; OPIATE SUBSTITUTION TREATMENT; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PHARMACIST; PHARMACY; PUBLIC HEALTH SERVICE; PUBLIC-PRIVATE PARTNERSHIP; QUALITY CONTROL; SEMI STRUCTURED INTERVIEW; SLEEP DISORDER; SPASTICITY; STANDARDIZATION; STIGMA; THEMATIC ANALYSIS; COOPERATION; DEMOGRAPHY; DRUG DEPENDENCE; HEALTH CARE QUALITY; LAW; MIDDLE AGED; PATHOLOGY; SOCIAL STIGMA; YOUNG ADULT;

ADULT; CANNABINOIDS; COOPERATIVE BEHAVIOR; DEMOGRAPHY; FEMALE; HUMANS; LEGISLATION AS TOPIC; MALE; MEDICAL MARIJUANA; MIDDLE AGED; PHARMACISTS; QUALITY ASSURANCE, HEALTH CARE; SOCIAL STIGMA; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84969900611     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155113     Document Type: Article

References (38)

1. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007; 4:1614-1648. PMID: 17712811
2. Caulkins JP, Hawken A, Kilmer B, Kleiman M. Marijuana Legalization: What Everyone Needs to Know: Oxford University Press; 2012.
3. Belackova V, Ritter A, Shanahan M, Chalmers J, Hughes C, Barratt M, et al. Medicinal cannabis in Australia-Framing the regulatory options. Sydney: Drug Policy Modelling Program. 2015. Available: https://ndarc.med.unsw.edu.au/resource/medicinal-cannabis-australia-framing-regulatory-options
4. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. J Am Med Assoc. 2015; 313:2456-2473.
5. The Australian National Council on Drugs. Medicinal use of cannabis: Background and Information Paper. Australian National Council on Drugs; 2014. Available: http://www.atoda.org.au/wp-content/uploads/ANCD-Medicinal-Cannabis-Information-Paper.pdf
6. Rauwendall E, Moxham-Hall V, Wodak A. Inquiry into the use of cannabis for medical purposes Australian Drug Law Reform Foundation: Submission to the NSW Parliamentary Enquiry: Australian Drug Law Reform Foundation 2013;1-15.
7. US Department of Health and Human-Services. FDA and Marijuana: Questions and Answers USA: US Food and Drug Administration 2015. Available: http://www.fda.gov/newsevents/publichealthfocus/ucm421168.htm-notapproved.
8. European Medicines Agency. EMA/655072/2010: Annual report of the European Medicines Agency. 2010. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-000643-PIP01-09/pip-000506.jsp&mid=WC0b01ac058001d129.
9. European Medicines Agency. EMA/737330/2012: Annual report of the European Medicines Agency. 2012. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-000181-PIP01-08-M01/pip-000125.jsp&mid=WC0b01ac058001d129.
10. European Medicines Agency. EMA/COMP/924925/2011: Annual report of the European Medicines Agency. 2011. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2011/12/human-orphan-001005.jsp&mid=WC0b01ac058001d12b.
11. Murphy J. Government support to allow the controlled cultivation of cannabis for medicinal or scientific purposes Department of Health - The Hon Sussan Ley MP. Department of Health Australia. 2015. Available: http://www.health.gov.au/internet/ministers/publishing.nsf/Content/546FB9EF48A2D570CA257EE1000B98F2/$File/SL-123.pdf.
12. Cummins P, Freckelton I, Buchanan L, Fatouros H, Gardner B, Hardingham I, et al. Medicinal Cannabis Report. Victorian Law Reform Commission. 2015. Available: http://www.lawreform.vic.gov.au/sites/default/files/VLRC-Cannabis-Issues-Paper-1.pdf
13. Rychert M, Wilkins C. Did we have the wrong debate about Elixinol and medicinal cannabis? The New Zeal Med J. 2015; 128:69-70.
14. Hardy PA. New Zealand doctors should be allowed to prescribe cannabis for pain: Yes. J Prim Health Care. 2015; 7:158-159. PMID: 26125063
15. Aamir T. New Zealand doctors should be allowed to prescribe cannabis for pain: No. J Prim Health Care. 2015; 7:160-161. PMID: 26125064
16. Charuvastra A, Friedmann PD, Stein MD. Physician attitudes regarding the prescription of medical marijuana. J Addict Dis. 2005; 24:87-93. PMID: 16186085
17. Ziemianski D, Capler R, Tekanoff R, Lacasse A, Luconi F, Ware MA. Cannabis in medicine: a national educational needs assessment among Canadian physicians. BMC Med Educ. 2015; 15:52. doi: 10.1186/s12909-015-0335-0 PMID: 25888752
18. Ebert T, Zolotov Y, Eliav S, Ginzburg O, Shapira I, Magnezi R. Assessment of Israeli Physicians' Knowledge, Experience and Attitudes towards Medical Cannabis: A Pilot Study. Isr Med Assoc J. 2015; 17:437-441. PMID: 26357721
19. Commonwealth of Australia. National Needle and Syringe Programs Strategic Framework 2010-2014. Victorian Department of Human Services. 2010. Available: http://health.gov.au/internet/publications/publishing.nsf/Content/illicit-pubs-needle-frame-toc
20. Australian Institute of Health and Welfare. National opioid pharmacotherapy statistics 2014. Bulletin no.128. Australian Institute of Health and Welfare. 2015. Available: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129551207
21. Glasier A, Baird D. The Effects of Self-Administering Emergency Contraception. N Engl J Med. 1998; 339:1-4. PMID: 9647872
22. Green J, Thorogood N. Qualitative methods for health research ( 3rd ed). Thousand Oaks, CA: Sage; 2013.
23. Australian Government Department of Health. The Poisons Standard 2015. Australian Government Department of Health. 2015. Available: https://www.comlaw.gov.au/Details/F2015L01534
24. Limentani AE. The role of ethical principles in health care and the implications for ethical codes. J Med Ethics. 1999; 25:394-398. PMID: 10536764
25. Kondrad E, Reid A. Colorado family physicians' attitudes toward medical marijuana. J Am Board Fam Med. 2013; 26:52-60. doi: 10.3122/jabfm.2013.01.120089 PMID: 23288281
26. Fleming GF, McElnay JC, Hughes CM, Sheridan J, Strang J. The role of the community pharmacist in drug abuse: a comparison of service provision between Northern Ireland and England/Wales. Pharm World Sci. 2001; 23:13-16. PMID: 11344585
27. Bammer G, Ritter A, Kutin JJ, Lintzeris N. Fast-tracking implementation through trial design: the case of buprenorphine treatment in Victoria. Aust N Z J Public Health. 2009; 33:34-39. doi: 10.1111/j.1753-6405.2009.00335.x PMID: 19236356
28. Samitca S, Huissoud T, Jeannin A, Dubois-Arber F. The role of pharmacies in the care of drug users: what has changed in ten years. The case of a Swiss region. Eur Addict Res. 2007; 13:50-56. PMID: 17172779
29. Bardet JD, Vo TH, Bedouch P, Allenet B. Physicians and community pharmacists collaboration in primary care: A review of specific models. Res Social Adm Pharm. 2015; 11:602-622. doi: 10.1016/j.sapharm.2014.12.003 PMID: 25640887
30. Bressler T, Persico L. Interprofessional education: Partnerships in the educational proc. Nurse Educ Pract. 2015 Jul 29. pii: S1471-5953(15)00118-3. doi: 10.1016/j.nepr.2015.07.004
31. Merrill JO, Jackson TR, Schulman BA, Saxon AJ, Awan A, Kapitan S, et al. Methadone medical maintenance in primary care. An implementation evaluation. J Gen Intern Med. 2005; 20:344-349. PMID: 15857492
32. Lintzeris N, Ritter A, Dunlop A, Muhleisen P. Training primary health care professionals to provide buprenorphine and LAAM treatment. Subst Abus. 2002; 23:245-254. PMID: 12438837
33. Okie S. Medical marijuana and the Supreme Court. N Engl J Med. 2005; 353:648-651. PMID: 16107619
34. Reiman AE. Self-efficacy, social support and service integration at medical cannabis facilities in the San Francisco Bay area of California. Health Soc Care Community. 2008; 16:31-41. doi: 10.1111/j.1365-2524.2007.00722.x PMID: 18181813
35. Winstock AR, Lea T, Sheridan J. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia. Addiction. 2010; 105:335-342. doi: 10.1111/j.1360-0443.2009.02774.x PMID: 20078490
36. Smith MY, Graham JA, Haddox JD, Steffey A. RxPATROL: a Web-based tool for combating pharmacy theft. J Am Pharm Assoc. 2009; 49:599-603.
37. Fichera GP, Sartori S, Costa G. [Post-traumatic stress disorder following robbery at the workplace: a pilot study on 136 pharmacy workers]. Med Lav. 2009; 100:97-108. PMID: 19382520
38. Chaar BB, Wang H, Day CA, Hanrahan JR, Winstock AR, Fois R. Factors influencing pharmacy services in opioid substitution treatment. Drug Alcohol Rev. 2013; 32:426-434. doi: 10.1111/dar.12032 PMID: 23442133